Bioblast Pharma competitors

Bioblast Pharma Competitors include Ultragenyx Pharmaceutical, Aevi Genomic Medicine, Vical and Sarepta Therapeutics.
Add company...
Bioblast Pharma
Bioblast Pharma
Bioblast Pharma Ltd., a clinical-stage biotechnology company, develops therapies for patients with rare and ultra-rare genetic diseases.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Aevi Genomic Medicine
Aevi Genomic Medicine
Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.
Vical
Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies.
Sarepta Therapeutics
Sarepta Therapeutics
Sarepta Therapeutics is a biopharmaceutical company focused on developing innovative RNA-targeted therapeutics.
Founding Date
Founding Date
2012
Founding Date
2010
Founding Date
2000
Founding Date
1987
Founding Date
1980
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Tel Aviv-Yafo, IL HQ
Locations
Novato, US HQ
Locations
Wayne, US HQ
San Francisco, US
Locations
San Diego, US HQ
Locations
Cambridge, US HQ
Employees
Employees
12
Employees
376
Employees
1729% decrease
Employees
74
Employees
197
Valuation ($)
Valuation ($)
3.9 m
Valuation ($)
2.9 b
Valuation ($)
14.9 m
Valuation ($)
21.6 m
Valuation ($)
9.3 b
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
65
Twitter followers
302

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$2.6m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$13.8m (FY, 2017)
Revenue (est.)
$154.6m (FY, 2017)
Cost of goods
Cost of goods
N/A
Cost of goods
$1k (FY, 2017)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$7.4m (FY, 2017)
Gross profit
Gross profit
N/A
Gross profit
$2.6m (FY, 2017)
Gross profit
N/A
Gross profit
N/A
Gross profit
$147.2m (FY, 2017)
Net income
Net income
($5.9m) (FY, 2017)
Net income
($302.1m) (FY, 2017)
Net income
($34.7m) (FY, 2017)
Net income
($13m) (FY, 2017)
Net income
($50.7m) (FY, 2017)

Funding

Total funding raised
Total funding raised
$ 4.8m
Total funding raised
$ 200.1m
Total funding raised
$ 7m
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Ultragenyx Pharmaceutical
HQ
Novato, US
Employees
376

Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.

View company
Aevi Genomic Medicine
HQ
Wayne, US
Employees
17↓ 29% decrease

Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.

View company
Vical
HQ
San Diego, US
Employees
74

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies.

View company
Sarepta Therapeutics
HQ
Cambridge, US
Employees
197

Sarepta Therapeutics is a biopharmaceutical company focused on developing innovative RNA-targeted therapeutics.

View company